{"entity":{"id":"bebetter-med","kind":"company","name":"BeBetter Med","aka":["BeBetter Medicine","Guangzhou BeBetter Medicine Technology"],"tldr":"BeBetter Med is a Guangzhou biotechnology company developing BEBT-908, a dual PI3K and HDAC inhibitor for relapsed lymphoma, and other small-molecule cancer drugs, with three late-stage trials in the registry.","summary":"BeBetter Med, based in Guangzhou, develops small-molecule cancer drugs. Its lead programme BEBT-908 inhibits both PI3K and histone deacetylases and has been studied in relapsed or refractory diffuse large B-cell lymphoma and other lymphomas, and the company runs further trials of its pipeline in solid tumours. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.bebettermed.com/"},{"label":"ClinicalTrials.gov: trials led by BeBetter Med","url":"https://clinicaltrials.gov/search?lead=BeBetter%20Med"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["dlbcl"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["bebt-209","ifupinostat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07544056","nct06792253","nct06998108","nct06514027","nct06706713"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Guangzhou","country":"CN","companyType":"biotech","website":"https://www.bebettermed.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/bebetter-med/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"bebt-209","kind":"drug","name":"BEBT-209","route":"/drugs/bebt-209/"},{"id":"ifupinostat","kind":"drug","name":"Ifupinostat","route":"/drugs/ifupinostat/"}],"trial":[{"id":"nct07544056","kind":"trial","name":"A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07544056/"},{"id":"nct06792253","kind":"trial","name":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct06792253/"},{"id":"nct06706713","kind":"trial","name":"Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer","route":"/trials/nct06706713/"},{"id":"nct06514027","kind":"trial","name":"Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations","route":"/trials/nct06514027/"},{"id":"nct06998108","kind":"trial","name":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","route":"/trials/nct06998108/"}]}}